Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06193928 · ClinicalTrials.gov registry record
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
A clinical trial of Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis, sponsored by Mirum Pharmaceuticals.
- Recruiting
- Registry status
- 70
- Enrollment target
- 8
- Study locations
NCT06193928 is a study of Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis that is actively recruiting participants, run by Mirum Pharmaceuticals. The registered enrollment target is 70 participants, above the 45-participant average among 3 other Alagille Syndrome trials with a reported enrollment target (56% higher). The trial reports 8 study locations across 7 states.
The verdict
NCT06193928, a study of Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis, is actively recruiting participants, sponsored by Mirum Pharmaceuticals.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
- 8
- Study locations
Study Summary
The objective of this 5-year, prospective, observational cohort study is to evaluate the long-term safety and clinical outcomes of patients with Alagille syndrome (ALGS) or Progressive familial intrahepatic cholestasis (PFIC) treated with Livmarli.
Conditions Studied
Interventions
- DRUG Livmarli
Study Locations (8)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children Hospital of Pittsburgh - Pittsburgh
California
- Children's Hospital Los Angeles CHLA - Los Angeles
Colorado
- Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics and the Digestive Health Institute, Children's Hospital of Colorado and University of Colorado - Aurora
Georgia
- Children's Healthcare of Atlanta - Emory University School of Medicine - Atlanta
Missouri
- Children's Mercy Kansas City, Department of Gastroenterology, Section of Hepatology - Kansas City
Oregon
- Oregon Health and Science University, Division of Pediatric Gastroenterology, Department of Pediatrics - Portland
Utah
- University of Utah, Division of Pediatric Gastroenterology, Hepatology and Nutrition - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2030-09-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06193928
The ClinicalTrials.gov registry entry for NCT06193928 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 45-participant average among 3 other Alagille Syndrome trials with a reported enrollment target (56% higher). The listed sponsor is Mirum Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alagille Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Livmarli is the first listed.
NCT06193928 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Pennsylvania, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06193928 about?
NCT06193928 is a clinical study titled "Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)". The objective of this 5-year, prospective, observational cohort study is to evaluate the long-term safety and clinical outcomes of patients with Alagille syndrome (ALGS) or Progressive familial intrahepatic cholestasis (PFIC) treated with Livmarli.
What is the current status of trial NCT06193928?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2023-09-21. Estimated completion is 2030-09-20.
What conditions does trial NCT06193928 study?
This clinical trial studies the following conditions: Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis.
What interventions are being tested in trial NCT06193928?
The interventions under investigation include: Livmarli (DRUG).
Who is sponsoring clinical trial NCT06193928?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06193928 being conducted?
This trial has 8 study locations across California, Colorado, Georgia, Missouri, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alagille Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
RECRUITING
-
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
RECRUITING · Phase 3
-
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
COMPLETED · Phase 2
Explore more on PlainTrial
Alagille Syndrome
All registered trials for this condition
Progressive Familial Intrahepatic Cholestasis
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.